Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
To develop and commercialize Lilly compounds employing ENHANZE platform
December 22, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Halozyme Therapeutics has entered a global collaboration and license agreement with Eli Lilly and Co. to develop and commercialize products combining Lilly compounds with Halozyme’s ENHANZE platform. Halozyme will receive $25 million upfront, along with milestone payments of as much as $160 million for each target, valued at as much as $800 million. Payments will be based on development, regulatory and sales-based milestones, as well as royalties on any products commercialized. The Halozyme ENHANZE platform uses a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan, a chain of natural sugars in the body, to aid in the dispersion and absorption of other injected therapeutic drugs. For Lilly, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery. “We are pleased to collaborate with innovators like Halozyme as we develop our pipeline assets and optimize them for the clinic,” said Divakar Ramakrishnan, Ph.D., vice president of delivery and device research and development at Lilly. “Halozyme’s ENHANZE technology will provide a platform for our scientists to optimize delivery of Lilly medicines through subcutaneous injection.” “Lilly is one of the most respected brands and innovators in pharmaceutical development and we are pleased to support their pipeline with our ENHANZE technology platform,” said Dr. Helen Torley, president and chief executive officer. “Through collaborators like Lilly, we see a growing opportunity to work both at an earlier stage of drug development as well as with products that are entering the clinic on formulations that have the potential to benefit patients worldwide.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !